Last updated: August 1, 2026
Intelence, the brand name for etravirine, is a second-generation non-nucleoside reverse transcriptase inhibitor approved for HIV-1 infection in treatment-experienced patients with resistance to other antiretroviral agents. Its clinical role has narrowed as integrase inhibitor-based regimens became the preferred standard of care. No major phase 3 development program or new indication expansion is publicly established through mid-2024. Intelence remains commercially relevant in selected multidrug-resistant HIV cases, but its market is mature, declining and exposed to generic substitution and regimen migration.
What is Intelence and how does etravirine work?
Intelence contains etravirine, an oral diarylpyrimidine NNRTI. It binds allosterically to HIV-1 reverse transcriptase and inhibits viral DNA synthesis. Its molecular flexibility gives it activity against some HIV-1 strains carrying resistance mutations to earlier NNRTIs, including efavirenz and nevirapine.
The FDA approved Intelence in January 2008 for use with other antiretroviral agents in treatment-experienced adults with HIV-1 strains resistant to an NNRTI and other antiretroviral agents. The approval was based principally on the DUET-1 and DUET-2 studies.
Intelence dosage forms and approved use
| Product |
Strength |
Administration |
| Intelence tablets |
25 mg |
Oral |
| Intelence tablets |
100 mg |
Oral |
| Intelence tablets |
200 mg |
Oral |
| Oral suspension |
Not a standard U.S. commercial dosage form |
Pediatric administration may require tablet dispersion under labeling instructions |
The labeled adult dose is 200 mg twice daily after a meal. Intelence is used with other active antiretroviral drugs and is not intended to function as monotherapy. The FDA label warns about severe skin reactions, hypersensitivity reactions, immune reconstitution inflammatory syndrome and interactions with CYP3A4, CYP2C9 and CYP2C19 substrates or inducers (FDA, 2024a).
What clinical trials support Intelence approval?
The pivotal evidence came from two randomized, double-blind, placebo-controlled phase 3 trials:
| Trial |
Population |
Treatment period |
Primary outcome |
| DUET-1 |
Treatment-experienced adults with NNRTI and protease inhibitor resistance |
24 weeks, with longer follow-up |
HIV-1 RNA below 50 copies/mL |
| DUET-2 |
Treatment-experienced adults with multidrug-resistant HIV-1 |
24 weeks, with longer follow-up |
HIV-1 RNA below 50 copies/mL |
In both trials, etravirine was administered with an optimized background regimen and compared with placebo plus the same background regimen. Etravirine produced higher rates of virologic suppression than placebo at the primary analysis and maintained a treatment advantage during follow-up (Katlama et al., 2009; Madruga et al., 2007).
The trials established the drug’s value in patients with limited treatment options. Their commercial relevance has diminished because the study populations and treatment setting differ from current first-line HIV practice, where integrase strand transfer inhibitors are generally preferred.
What is the current Intelence clinical trial pipeline?
Intelence has no publicly established late-stage clinical program aimed at a new HIV indication through mid-2024. Current clinical activity is more likely to involve:
- Observational studies of treatment-experienced patients.
- Retrospective analyses of resistance and salvage regimens.
- Pharmacokinetic studies involving drug interactions.
- Pediatric or special-population evaluations.
- Comparative studies of older antiretroviral combinations.
The clinical development outlook is limited. Etravirine is unlikely to receive substantial investment for first-line therapy, long-acting delivery or combination products unless a specific resistance-management need creates a commercial rationale. Cabotegravir, rilpivirine, dolutegravir, bictegravir and boosted darunavir-based approaches have greater strategic priority in current HIV development.
What clinical risks affect continued use?
The main clinical constraints are dosing frequency, food requirements, drug interactions and the availability of better tolerated or more convenient alternatives. Etravirine also has a lower strategic position than integrase inhibitors for patients without extensive resistance.
Clinical value remains strongest when:
- A patient has documented NNRTI resistance.
- The optimized background regimen includes other active agents.
- Integrase inhibitor options are limited or unsuitable.
- A clinician needs an oral component of salvage therapy.
What is the FDA regulatory status of Intelence?
Intelence is FDA-approved and marketed as a prescription antiretroviral. The original U.S. application is NDA 022187. Janssen Products, LP is identified in U.S. product and labeling materials as the manufacturer or application holder associated with Intelence.
The FDA approval is for treatment-experienced HIV-1 patients, not for routine initial therapy. The product remains subject to labeling requirements for resistance testing, combination use and administration after a meal.
What is the Orange Book status of Intelence?
Intelence is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under etravirine. Orange Book entries and patent or exclusivity information can change through patent delistings, certifications, pediatric extensions and regulatory updates. The commercial question is no longer only the nominal patent term. It is whether an approved generic can achieve sufficient volume and reimbursement access to justify launch.
The relevant U.S. regulatory pathway for a generic etravirine tablet would generally be an ANDA demonstrating pharmaceutical equivalence and bioequivalence to the reference listed drug. A Paragraph IV certification could challenge any listed patent that remains relevant at the time of ANDA filing.
What patents protect Intelence and when does etravirine lose exclusivity?
Intelence’s principal composition-of-matter protection was based on early etravirine patent filings and has a later expiration profile than the 2008 approval date because of patent-term adjustment and possible regulatory exclusivity. The original composition patents are no longer the central commercial barrier in the same way they were during the product’s launch period.
Potential protection categories include:
- Etravirine composition-of-matter claims.
- Solid-state or crystalline-form claims.
- Tablet formulation claims.
- Manufacturing-process claims.
- Dosage and treatment-method claims.
- Pediatric or regulatory exclusivity tied to clinical studies.
The practical U.S. loss-of-exclusivity window depends on the specific Orange Book-listed patents, pediatric extensions and any Paragraph IV litigation. Generic entry cannot be estimated reliably from the 2008 approval date alone. The FDA Orange Book and patent litigation docket are the controlling sources for a transaction or launch decision (FDA, 2024b).
How strong is the Intelence patent estate?
The estate is commercially weaker than the estates supporting newer HIV products. Etravirine’s core molecule is mature, and the product has a narrow treatment-experienced population. Later patents covering formulations, processes or specific methods may create litigation leverage, but they are less likely to sustain substantial branded pricing if a therapeutically substitutable generic becomes available.
Patent strength is therefore moderate to weak from a market-defense perspective:
| Patent factor |
Assessment |
| Core molecule |
Mature and likely expired or near the end of enforceable life in major markets |
| Formulation claims |
Potentially relevant but narrower |
| Method-of-use claims |
Limited by a specialized label and prescribing practice |
| Manufacturing claims |
Can complicate supply but rarely preserve broad commercial exclusivity alone |
| Market impact |
Reduced by small patient population and alternative regimens |
Which companies are challenging Intelence with generics?
Publicly visible competition has been limited compared with high-volume antiretrovirals. The commercial threat comes from three sources:
- An approved generic etravirine product entering the U.S. market.
- Generic or local manufacturers in jurisdictions where patent barriers have expired.
- Therapeutic substitution by other branded or generic antiretrovirals.
A Paragraph IV challenge is meaningful only if it is tied to an ANDA accepted by FDA and followed by litigation or a settlement. No broad, high-profile U.S. challenge comparable to the litigation surrounding major blockbuster drugs defines Intelence’s current competitive landscape through mid-2024.
What generic launch scenarios exist?
| Scenario |
Commercial outcome |
| No near-term approved generic |
Intelence retains a small protected niche, with declining volume |
| One generic entrant |
Rapid price erosion is likely because the market is concentrated and prescribers can substitute |
| Multiple generic entrants |
Commodity pricing and reduced branded share |
| Generic entry plus regimen migration |
Steeper decline because patients may switch away from etravirine entirely |
| Supply disruption |
Short-term branded demand could rise, but durable market recovery is unlikely |
What is the Intelence market outlook?
Intelence is a niche HIV product rather than a growth asset. Its addressable market is limited to treatment-experienced patients who need an NNRTI with activity against selected resistant virus. The overall HIV market continues to grow in patient numbers, but growth is concentrated in newer regimens, long-acting therapies and fixed-dose combinations.
Market drivers
The principal demand drivers are:
- Persistent global HIV prevalence.
- Long-term treatment duration.
- Multidrug-resistant HIV cases.
- Use in resource-constrained settings where older regimens remain available.
- Individualized salvage therapy.
Market restraints
The main restraints are:
- Preference for integrase inhibitor-based therapy.
- Generic competition.
- Twice-daily dosing.
- Food-dependent administration.
- Drug-interaction burden.
- Small eligible population.
- Reduced clinical trial and promotional investment.
- Competition from darunavir, dolutegravir, bictegravir, cabotegravir and rilpivirine-based regimens.
What is the revenue exposure for Intelence?
Janssen does not generally disclose Intelence revenue as a separately material product line in public corporate reporting. Revenue exposure is therefore best assessed qualitatively rather than through a company-reported product forecast.
Intelence likely represents a low-value asset relative to the manufacturer’s oncology, immunology and broader infectious-disease portfolios. Its value is more likely to arise from residual cash flow, portfolio continuity and access in selected markets than from significant revenue growth.
How does Intelence compare with competing HIV drugs?
| Product or class |
Main advantage over Intelence |
Intelence advantage |
| Dolutegravir |
High potency, once-daily dosing, broad guideline use |
Useful when resistance or intolerance limits alternatives |
| Bictegravir |
Fixed-dose combination and once-daily administration |
More established role in selected salvage settings |
| Cabotegravir plus rilpivirine |
Long-acting administration |
Intelence is oral and does not require injection infrastructure |
| Darunavir-based regimens |
High barrier to resistance |
Etravirine may add activity in selected resistant virus |
| Efavirenz or nevirapine |
Lower cost in some markets |
Etravirine generally has a better resistance profile |
| Generic NRTI combinations |
Low cost and broad availability |
Etravirine retains niche value for resistant HIV |
What licensing deals and partnerships involve Intelence?
Intelence was developed and commercialized through Tibotec, which became part of Janssen Pharmaceuticals and Johnson & Johnson. No major recent licensing transaction has materially changed Intelence’s global commercial position through mid-2024.
The product’s strategic value is tied to Janssen’s HIV portfolio and distribution infrastructure rather than a visible external licensing expansion. Any future transaction would likely focus on regional rights, mature-brand commercialization or generic-style supply arrangements rather than new global clinical development.
What patent litigation and settlement agreements affect Intelence?
Intelence has not generated a publicly prominent wave of U.S. patent litigation comparable with large antiretroviral products such as Truvada, Atripla or certain newer combination products. The key legal risks remain:
- Paragraph IV challenges to listed patents.
- ANDA litigation concerning formulation or method claims.
- Patent-term disputes.
- Patent settlements that delay generic launch.
- International disputes over manufacturing or supply.
A settlement could include a licensed entry date, authorized generic terms, royalty provisions or restrictions on formulation and indication claims. The absence of a widely reported settlement does not establish that no confidential or regional agreement exists.
What manufacturing and geographic IP barriers apply to Intelence?
Etravirine manufacturing is less strategically difficult than biologic production because Intelence is a small-molecule oral tablet. The main barriers are:
- Control of active pharmaceutical ingredient quality.
- Solid-state and particle-size control.
- Tablet dissolution and bioequivalence.
- Stability during storage.
- Regulatory documentation for an ANDA or local equivalent.
- Supply-chain qualification in regulated markets.
Geographic exclusivity varies. U.S. patent and FDA status do not determine entry in Europe, Canada, Latin America, India, Africa or Southeast Asia. Local patent expiration, compulsory licensing rules, procurement tenders and national treatment guidelines can create earlier generic access outside the United States.
What is the Intelence market projection through 2030?
The base-case projection is continued low-single-digit to mid-single-digit annual revenue decline for the branded product, with steeper erosion if a widely distributed generic launches in the United States or major European markets.
| Period |
Base-case expectation |
| 2024-2025 |
Stable-to-declining niche demand; no major clinical expansion |
| 2026-2027 |
Greater generic and therapeutic-substitution pressure |
| 2028-2030 |
Mature residual market concentrated in salvage therapy and selected geographies |
The upside case requires sustained demand from resistant HIV, limited generic competition and continued supply availability. The downside case involves multiple generic entrants, reimbursement pressure and rapid migration to integrase inhibitor-based regimens.
Key Takeaways
- Intelence is etravirine, a second-generation NNRTI for treatment-experienced HIV-1 patients.
- Its approval was supported by the DUET-1 and DUET-2 phase 3 trials.
- No major late-stage clinical development program or broad new indication is established through mid-2024.
- The drug’s clinical role is concentrated in multidrug-resistant or otherwise difficult-to-treat HIV.
- The market is mature and declining because of integrase inhibitor adoption, generic risk and twice-daily administration.
- Patent value is concentrated in residual formulation, process and method claims rather than a durable growth-oriented composition estate.
- Generic entry would likely produce rapid price erosion because the eligible population is small and alternative regimens are available.
- Intelence remains a niche cash-flow product, not a major HIV growth asset.
FAQs About Intelence
Is Intelence still prescribed?
Yes. It remains an option for selected treatment-experienced patients, particularly when resistance limits other antiretroviral choices.
Is etravirine a first-line HIV treatment?
No. Current treatment guidelines generally favor integrase inhibitor-based regimens for most people starting HIV therapy.
Can Intelence be used alone?
No. Etravirine must be combined with other active antiretroviral medicines.
Does Intelence have a long-acting injectable version?
No. Intelence is an oral tablet. Its twice-daily dosing differs from long-acting cabotegravir and rilpivirine regimens.
What is the main investment risk for Intelence?
The main risk is structural market decline from generic substitution and migration to newer, simpler antiretroviral regimens, rather than a sudden loss of clinical utility.
References
-
Food and Drug Administration. (2024a). Intelence (etravirine) prescribing information. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Katlama, C., Haubrich, R., Lalezari, J., Lazzarin, A., Unsal, K., Debyser, Z., ... DUET-2 investigators. (2009). Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: 48-week results of the phase III DUET-2 trial. AIDS, 23(17), 2289-2300.
-
Madruga, J. V., Cahn, P., Grinsztejn, B., Haubrich, R., Lalezari, J., Mills, A., ... DUET-1 investigators. (2007). Efficacy and safety of etravirine in treatment-experienced HIV-1-infected patients: Primary 24-week analysis of the phase III DUET-1 trial. The Lancet, 370(9581), 29-38.
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
